{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:54Z","timestamp":1794978654890,"version":"4.9.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,5]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>CD19\u2212 relapses are a major challenge in about 10% to 20% of patients treated with blinatumomab. Molecular workup of 1 case revealed a disrupted CD19 membrane export as the basis for blinatumomab resistance.<\/jats:p>","DOI":"10.1182\/blood-2016-05-718395","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T23:28:31Z","timestamp":1477524511000},"page":"100-104","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":254,"title":["Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking"],"prefix":"10.1182","volume":"129","author":[{"given":"Friederike","family":"Braig","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum\/University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brandt","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum\/University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Goebeler","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Internal Medicine II, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[{"name":"Rheumatology\/Clinical Immunology, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Katharina","family":"Kurze","sequence":"additional","affiliation":[{"name":"Research Institute Children\u2019s Cancer Center, Hamburg, Germany;"},{"name":"Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nollau","sequence":"additional","affiliation":[{"name":"Research Institute Children\u2019s Cancer Center, Hamburg, Germany;"},{"name":"Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bumm","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Internal Medicine II, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[{"name":"Division of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum\/University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111907270207200_B1","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"issue":"26","key":"2019111907270207200_B2","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"36","key":"2019111907270207200_B3","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111907270207200_B4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111907270207200_B5","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111907270207200_B6","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","article-title":"Monoclonal antibodies in acute lymphoblastic leukemia","volume":"125","author":"Jabbour","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111907270207200_B7","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111907270207200_B8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111907270207200_B9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"issue":"1","key":"2019111907270207200_B10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cyto.b.20071","article-title":"Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children\u2019s oncology group","volume":"68","author":"Borowitz","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"2019111907270207200_B11","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/leu.2016.64","article-title":"BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance","volume":"30","author":"Weiland","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2019111907270207200_B12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"7","key":"2019111907270207200_B13","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/leu.2016.18","article-title":"The possible perils of targeted therapy","volume":"30","author":"Duffner","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2019111907270207200_B14","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2019111907270207200_B15","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"2019111907270207200_B16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J"},{"issue":"7404","key":"2019111907270207200_B17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"issue":"4","key":"2019111907270207200_B18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI39748","article-title":"CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency","volume":"120","author":"van Zelm","year":"2010","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/1\/100\/1398311\/blood718395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/1\/100\/1398311\/blood718395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:27:29Z","timestamp":1574148449000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/1\/100\/35801\/Resistance-to-antiCD19CD3-BiTE-in-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-05-718395","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]}}}